GI Stool Testing Market - By Product Type (Consumables, Analyzers), By Test Type (Occult Blood Test, Fecal Biomarkers Test), By Application (Infection, Cancer), By Distribution Channel (Brick & Mortar, E-commerce), By End-use (Hospitals & Clinics, Homecare Settings), & Forecast, 2023 – 2032.

GI Stool Testing Market - By Product Type (Consumables, Analyzers), By Test Type (Occult Blood Test, Fecal Biomarkers Test), By Application (Infection, Cancer), By Distribution Channel (Brick & Mortar, E-commerce), By End-use (Hospitals & Clinics, Homecare Settings), & Forecast, 2023 – 2032.

GI Stool Testing Market Size

GI Stool Testing Market size was valued at around USD 600.1 million in 2022 and is estimated to reach over USD 1.2 billion by the end of 2032. The increasing prevalence of gastrointestinal diseases is anticipated to drive the market growth globally.
 

The rising incidence of colorectal cancer (CRC) is owing to factors including unhealthy lifestyle, diabetes, and ageing population, among others thereby driving market expansion. For instance, according to the reports published by the American Society of Clinical Oncology (ASCO), in 2020, approximately around 1,880,725 individuals were diagnosed with colorectal cancer across the globe.
 

GI stool testing tests delivers certain clinical benefits over conventional diagnostic procedures, such as rapid specimen handling, simpler sample requirements, increased automation, and rapid results. As a result, the demand for GI stool testing is proliferating, especially in the emerging economies that possess immense market value. Moreover, the increased usage and demand for these testing procedures in hospital settings is expected to develop business growth opportunities.
 

GI stool testing products are utilized for the diagnosis of gastrointestinal diseases comprising infection, inflammatory bowel disease, gastroesophageal reflux disease (GERD), and cancer among others. These testing products include an occult blood test, parasites test, bacteria test, and fecal biomarkers test among others that are employed in the detection and treatment of certain gastrointestinal conditions.
 

However, gastrointestinal diseases can be diagnosed with different testing techniques comprising GI stool testing. These tests require accurate operational skills for precise diagnosis to evaluate appropriate treatment. Thus, the lack of skilled professionals in countries with limited healthcare resources can hamper the disease testing rate, thereby impacting the industry revenue.
 

COVID-19 Impact

The recent outbreak of COVID-19 had negatively impacted the GI stool testing market size. The lucrative demand for COVID-19 testing had substantially impacted other disease testing services. During the initial period, the incidence, as well as the mortality rate of COVID-19, was highest, and people tended to avoid any other treatment or diagnosis procedures at facilities. The risk of infection during invasive GI stool testing at point-of-care facilities had resulted in procedure deferral.
 

In addition, the high rate of COVID-19 incidence across the globe had driven the need for expansion of existing testing facilities. These factors had shifted focus on increasing COVID-19 testing-related services leading to the decline in the point-of-care testing of other diseases including GI testing, thus impeding the related product sales during the period. However, the COVID-19 infection estimated to cause some gastrointestinal diseases. A considerable portion of patients with COVID-19 infections was diagnosed with GI diseases that had continued the need for disease testing to a certain limit.
 

GI Stool Testing Market Trends

The increasing prevalence of gastrointestinal diseases is anticipated to proliferate market expansion. Growing baby boomer generation suffering from gastrointestinal infections have accelerated the demand for diagnostic procedures that has further propelled the market landscape. Gastrointestinal disorders such as digestive tract bleeding, ulcers, chronic pancreatitis, ulcerative colitis (UC), inflammatory bowel disease (IBD), and abnormal growth in the GI tract promote substantial disease burden. These ailments inflict the health care costs and affect the health-associated quality of life. According to the American Gastroenterology Association (AGA) publication 2021, more than 40% of individuals globally suffer from functional gastrointestinal disorders (FGIDs) that include a variety of GI conditions.
 

Further, rising incidence of chronic diseases including gastrointestinal cancer leads to a large number of patients opting stool test for diagnosis. In the U.S., colorectal cancer (CRC) is the 3rd most commonly diagnosed cancer and the 3rd most common cause of cancer-related death in both men and women. Hence, owing to the above statistics rising prevalence of gastrointestinal disorders is set to increase the demand for diagnostic procedures that will prove beneficial for the business progress.
 

GI Stool Testing Market Analysis

Based on product type, the GI stool testing market is segmented as consumables and analyzers. The consumables segment was valued at over USD 376 million in 2022. This segment share is primarily attributed to a significant increase in the preference for GI disease diagnostic reagents and test kits that are used to examine a range of GI-health issues such as infection, inflammatory bowel disease, and cancer among others by diagnosing & screening.
 

Market players are emphasizing on the designing of reagents to address the growing and evolving needs for GI testing in diagnostics centers and hospitals. The ongoing R&D activities are focused to deliver superior quality & excellent performance consumables that are utilized in GI stool testing for most demanding applications.
 

Based on test type, the GI stool testing market is segmented as occult blood test, ova and parasites test, bacteria test, fecal biomarkers test, and others. Fecal occult blood test (FOBT) segment held a dominant revenue share and was valued at over USD 281 million in 2022 and is expected to witness a significant growth trend during the analysis period. This is primarily attributed to a significant increase in the preference for early diagnosis and better therapeutic results among patient suffering from gastrointestinal issues such as cancer, polyps, ulcers, or haemorrhoids.  
 

The presence of blood in the stool sample indicates bleeding in the digestive tract and is considered as initial phase of the colorectal cancer. Some of the major causes of bleeding bladder include polyps, haemorrhoids, diverticulosis, ulcers, colitis, etc. For instance, according to European Crohn’s and Colitis Organisation (ECCO) data, in 2020, the incidence rate of ulcerative colitis in Europe was estimated to be around 2.4 to 44 per 100,000 individuals and is expected to rise at a steady pace. Therefore, in order to test and detect the occurrence of gastrointestinal complications among patients, fecal occult blood test (FOBT) is increasingly preferred by several healthcare professionals.
 

Based on application, the GI stool testing market is segmented as infection, inflammatory bowel disease, gastroesophageal reflux disease (GERD), cancer and others. Gastrointestinal infection segment dominated the market with more than 38% revenue share in 2022 and is forecasted to witness a similar trend during the analysis period. This is attributable to the growing prevalence of GI infection and preference for technologically advanced GI diagnostic tests, etc.  
 

Moreover, benefits associated with testing such as reliability in disease screening and reduction in the severity of infection with a better diagnosis are forecasted to positively impact the industry growth. Recent research studies have observed that H. pylori cause the majority of gastric ulcers. The highest incidence rate in developed, as well as some developing regions, is further augmenting the product adoption.
 

Based on distribution channel, the GI stool testing market is segmented as the hospital & clinics pharmacies, brick & mortar, and e-commerce. The brick & mortar stores segment is estimated to progress at substantial growth rate to reach USD 538 million by end of 2032. This substantial segment share is owing to several advantages offered by the medical retail stores in diagnostic tests distribution including the availability of a wide array of tests and substantial discounts.
 

Additionally, various market players are focusing on marketing products through medical retail stores that increase the salability of a wide variety of product, thus propelling segmental growth. Some medical retail stores also offer educational programs for precise product awareness and focus on combating health issues including GI diseases, etc. Moreover, well-defined safety, effective services, and security policies are boosting the segment revenue.
 

Based on end-use, the market is segmented as hospitals & clinics, diagnostic centers, homecare settings, and others. The hospitals & clinics segment held a majority GI stool testing market share in 2022 and is projected to reach more than USD 597 million by 2032. The soaring use of novel GI stool tests in hospital & clinical settings delivering rapid and reliable outcomes is estimated to surge the patient preference for these healthcare facilities. The availability of a broad spectrum of kits and instruments for performing these tests with proven accuracy is set to drive product preference in hospitals.
 

Growing admissions with GI ailments and growing disease screening initiatives along with the accessibility to board-certified healthcare professionals are some other variables that are augmenting the segment trends positively. Furthermore, the rising disease burden in developed economies with enhanced healthcare infrastructure is projected to stimulate the diagnosis & treatment rate at hospitals.
 

U.S GI stool testing market and was valued at around USD 254 million in 2022. This high market share is primarily attributed to several factors such as the presence of major industry players, rising prevalence of gastrointestinal disorders, etc. According to the Centers for Disease Control and Prevention (CDC) data 2021, peptic ulcer affects around 4.6 million adults every year in the U.S. As per the National Ambulatory Medical Care Survey recent data, more than 54 million patients had performed diagnosis for the diseases of the digestive systems in the U.S. Thus, gastrointestinal diagnostic procedures have been significantly rising in the U.S. over the past few years.
 

Additionally, the presence of prominent players such as Abbott Laboratories, Cardinal Health, and Meridian Bioscience Inc. among others in the country are engaged in new product development & commercialization that facilitates industrial expansion in the U.S.
 

GI Stool Testing Market Share

Some of the major market players operating in the GI stool testing market are

• Abbott Laboratories, Alere Inc
• Beckman Coulter Inc
• Bio Rad Laboratories
• BioMrieux Inc
• Cardinal Health

Major market players are adopting strategic formulations such as forward integration, new product development, geographical expansion, and research collaborations to garner maximum industry share and promote company growth.
 

GI Stool Testing Industry News

• In April 2020, Qiagen announced the launch of novel therascreen BRAF V600E RGQ PCR Kit (therascreen BRAF V600E Kit) in metastatic colorectal cancer. This product is intended for use in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC). This strategic product launch helped the company to increase their product portfolio and enhance their business revenue.
   
• In November 2018, Quest Diagnostics announced a 5-year extensive strategic partnership with Clinical Genomics for the supply of InSur ONE faecal immunochemical test (FIT) in the U.S. This strategic partnership allowed the company to increase their customer base and enter their reach in untapped areas.
   

GI stool testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD (million) and volume (units) from 2018 to 2032 for the following segments

Click here to Buy Section of this Report

By Product Type, 2018 - 2032 (USD Million & Units)

• Consumables
• Analyzers

By Test Type, 2018 - 2032 (USD Million)

• Occult Blood Test
  • Guaiac FOB Stool Test
  • Immuno FOB Agglutination Test
  • Lateral Flow Immuno FOB Test
  • Immuno FOB ELISA Test
• Ova and Parasites Test
• Bacteria Test
• Fecal Biomarkers Test
  •  Tumor M2-PK Stool Test
  • Transferrin Assays
  • Others
• Others

By Application, 2018 - 2032 (USD Million)

• Infection
• Inflammatory Bowel Disease
• Gastroesophageal Reflux Disease (GERD)
• Cancer
• Others

By Distribution Channel, 2018 - 2032 (USD Million)

• Hospital & clinics pharmacies
• Brick & Mortar
• E-commerce

By End-use, 2018 - 2032 (USD Million)

• Hospitals & Clinics
• Diagnostic Centers
• Homecare Settings
• Others

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Sweden
  • The Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Indonesia
  • Philippines
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Iran